We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 22, 2020

Effect of Dose-Dense Adjuvant Chemotherapy in HR+/HER2− Early Breast Cancer According to Luminal Subtype

European Journal of Cancer


Additional Info

European Journal of Cancer
Effect of Dose-Dense Adjuvant Chemotherapy in Hormone Receptor Positive/HER2-Negative Early Breast Cancer Patients According to Immunohistochemically Defined Luminal Subtype: An Exploratory Analysis of the GIM2 Trial
Eur. J. Cancer 2020 Sep 01;136(xx)43-51, B Conte, M Bruzzone, M Lambertini, F Poggio, C Bighin, E Blondeaux, M De Laurentiis, E Valle, F Cognetti, C Nisticò, S De Placido, O Garrone, T Gamucci, F Montemurro, F Puglisi, B Cardinali, P Fregatti, L Miglietta, F Boccardo, M Ceppi, L Del Mastro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading